MedTrace Logo

Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

NCT01316549 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2021-10-04

No results posted yet for this study

Summary

Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of fludarabine in their bodies and if drug levels are related to whether or not a child experiences severe side-effects during their bone marrow transplant. The hypothesis is that clinical and genetic factors cause changes in fludarabine drug levels in pediatric bone marrow transplant patients and that high levels may cause severe side-effects.

Conditions

Interventions

DRUG

Fludarabine

Given as injection

Sponsors & Collaborators

Principal Investigators

  • Janel R Long-Boyle, PharmD, PhD · University of California, San Francisco

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2016-04-30
Completion
2016-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316549 on ClinicalTrials.gov